ENTRY       D10913                      Drug
NAME        Burosumab (USAN/INN);
            Burosumab (genetical recombination) (JAN);
            Burosumab-twza;
            Crysvita (TN)
PRODUCT     CRYSVITA (Kyowa Kirin)
            CRYSVITA (Ultragenyx Pharmaceutical)
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT NHYMHWVRQA PGQGLEWMGI INPISGSTSN
            AQKFQGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARDI VDAFDFWGQG TMVTVSSAST
            KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY
            SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV
            FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY
            RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK
            NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG
            NVFSCSVMHE ALHNHYTQKS LSLSPGK
            (Light chain)
            AIQLTQSPSS LSASVGDRVT ITCRASQGIS SALVWYQQKP GKAPKLLIYD ASSLESGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNDYFTFGPG TKVDIKRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: H22-H96, H144-H200, H220-L213, H220-H'226, H229-H'229, H261-H321, H367-H425, H'22-H'96, H'144-H'200, H'220-L'213, H'261-H'321, H'367-H'425, L23-L88, L133-L193, L'23-L'88, L'133-L'193)
  TYPE      Peptide
REMARK      Therapeutic category: 3999
            ATC code: M05BX05
            Product: D10913<JP/US>
EFFICACY    Antifibroblast growth factor antibody
  DISEASE   X-linked hypophosphatemia [DS:H02143]
  TYPE      Monoclonal antibody
COMMENT     Treatment of X-linked hypophosphatemia, tumor-induced osteomalacia
TARGET      FGF23 [HSA:8074] [KO:K22428]
  PATHWAY   hsa04010(8074)  MAPK signaling pathway
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             M MUSCULO-SKELETAL SYSTEM
              M05 DRUGS FOR TREATMENT OF BONE DISEASES
               M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
                M05BX Other drugs affecting bone structure and mineralization
                 M05BX05 Burosumab
                  D10913  Burosumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Burosumab
               D10913  Burosumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D10913  Burosumab (USAN/INN); Burosumab (genetical recombination) (JAN)
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Growth factors (RTK-binding)
                FGF23
                 D10913  Burosumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10913
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10913
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10913
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10913
DBLINKS     CAS: 1610833-03-8
            PubChem: 342581770
///
